Show simple item record

dc.contributor.authorHutchinson, John
dc.contributor.authorISARIC4C Investigators
dc.date.accessioned2020-11-13T17:11:59Z
dc.date.available2020-11-13T17:11:59Z
dc.date.issued2020-10
dc.identifier.citationDrake TM, et al., ISARIC4C Investigators. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study. Am J Respir Crit Care Med. 2020 Oct 2. doi: 10.1164/rccm.202007-2794OC. Epub ahead of print. PMID: 33007173.en
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/2334
dc.descriptionThis article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).en
dc.description.abstractRationale: The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporaneous age, sex and comorbidity matched population. Methods: An international multicenter audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death. Measurements and Main Results: Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and co-morbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 2.27, 1.39-3.71). Conclusions: Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.en
dc.language.isoenen
dc.subjectCOVID-19en
dc.subjectClinical Trialen
dc.subjectObesityen
dc.subjectLung Functionen
dc.subjectInterstitial Lung Diseaseen
dc.titleOutcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study.en
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record